← brief for 2026-08-21 · Slowing decline

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

Trial No results yet Not peer reviewed

Key takeaways

A new study is starting. It will test whether the drug empagliflozin changes signs of kidney cell damage that show up in the urine. The people in it are African American military veterans with kidney disease not caused by diabetes. It is just beginning, so there are no results yet.

Who did this work

Run by Washington D.C. Veterans Affairs Medical Center. Sabyasachi Sen, MD (Washington VA Medical Center)
Sites: Washington DC Veterans Affairs Medical Center (688)

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-21
https://clinicaltrials.gov/study/NCT06110130